Manufacturing and characterization services for vaccines and other biologics for infectious diseases
Ended Indefinite Delivery Contract Awarded Last action
- Contract number
- 75N93018D00009
- Awardee
-
Advanced Bioscience Laboratories, Inc. UEI MK4QC9EKZXG8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Task orders
- 10 $7,732,060 obligated
Award facts
- Opportunity
-
- RFPDMIDNIAIDNIHAI2017089 Solicitation number
- Combined order value
-
- $7,732,060 Current, with exercised options
- $8,217,262 Potential, with all options
- Last date to order 100% complete
- IDV ceiling 10% used
- $80,000,000.00
- Award type
- Multiple award
- Who can order
- Only the awarding agency
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
This Indefinite Delivery Contract (IDC) was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Advanced Bioscience Laboratories, Inc. (ABL), a leading contract research and manufacturing organization. The $80 million IDC is for manufacturing and characterization services for vaccines and other biologics targeting infectious diseases.
Under this IDC, ABL has been issued multiple task orders for a range of services, including cGMP manufacturing of vaccines and biologics, process development, analytical testing, stability studies, and project management support for infectious disease countermeasures such as HIV, influenza, and other vaccines and therapeutics. The task orders, valued at over $5.4 million, cover activities like master cell bank production, formulation development, process development for a panfungal vaccine, and stability testing for a vaccine adjuvant. These task orders are part of ABL's broader work with NIAID, the National Cancer Institute (NCI), and the National Institute of Neurological Disorders and Stroke (NINDS) under various IDCs to advance the development of medical countermeasures across multiple disease areas.
Task orders
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Modification | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 |
Quick answers
Who was awarded contract 75N93018D00009?
75N93018D00009 was awarded to Advanced Bioscience Laboratories, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on May 15, 2018.
How much is contract 75N93018D00009 worth?
Orders under 75N93018D00009 have obligated $7,732,060. Their combined potential value, with all options, is $8,217,262. 75N93018D00009's own ceiling is $80,000,000.
How many orders have been placed under contract 75N93018D00009?
10 orders have been placed under 75N93018D00009, the latest on September 26, 2023.
Who can order from contract 75N93018D00009?
75N93018D00009 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract 75N93018D00009 competed?
The extent of competition for 75N93018D00009 was full and open competition. The government received 3 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV